Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763880 · ClinicalTrials.gov registry record · Phase 4
Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction
A Phase 4 study, sponsored by Rhode Island Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00763880: Clinical Trial Phase 4 study, sponsored by Rhode Island Hospital.
NCT00763880 is a Phase 4 study that was terminated before completion, run by Rhode Island Hospital. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00763880, a Phase 4 study, was terminated before completion, sponsored by Rhode Island Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of our study is to determine if the use of a hematoma block together with intravenous sedation and analgesia is an effective means of managing forearm fractures in the Emergency Department. To determine this, we have designed a randomized, double-blind, placebo controlled trial of hematoma block versus saline for the manipulation of forearm fractures under conscious sedation with ketamine and midazolam. Our hypotheses are two-fold: First, the use of a hematoma block together with conscious sedation will allow for improved pain control. Second, the use of a hematoma block together with conscious sedation will allow us to use less sedation, therefore promoting faster recovery from sedation and more efficient patient turnover in the Emergency Department.
Interventions
- DRUG Saline
- DRUG Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Why NCT00763880 stopped before completion
NCT00763880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00763880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00763880 about?
NCT00763880 is a clinical study titled "Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction". The purpose of our study is to determine if the use of a hematoma block together with intravenous sedation and analgesia is an effective means of managing forearm fractures in the Emergency Department. To determine this, we have designed a randomized, double-blind, placebo controlled trial of hemato...
What is the current status of trial NCT00763880?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2005-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00763880?
The interventions under investigation include: Saline (DRUG), Lidocaine (DRUG).
Who is sponsoring clinical trial NCT00763880?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00763880's enrollment target sits among peer trials
89 913th of 2000 higher than 1,085 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia